1. Generics Bulletin
  2. >>Products

Amphastar Delivers Strong Quarter With Epinephrine Gains

As Company’s US Glucagon Rival Performs Well

 
• By Akriti Seth

Amphastar delivers back-to-back strong quarters as the company continues to see a rise in sales of its key products including Primatene Mist (epinephrine), glucagon and other epinephrine products. The company continues to build its pipeline and diversify its portfolio.

Gain
Company sees 34% increase in Primatene Mist (epinephrine) sales in Q2 FY21 • Source: Alamy

Amphastar Pharmaceuticals, Inc. has delivered another strong quarter on the back of increased volumes of higher margin products including Primatene Mist (epinephrine). The company reported net revenues of $101.7m for the second quarter ending 30 June 2021, compared with $85.8m reported in the prior-year period. The sale of Primatene Mist alone saw an increase of 34% to $16.6m in Q2 FY21, compared to Q2 FY20.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products